Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc is a clinical-stage biotechnology company focused on pioneering new therapeutics in orexin-based neuroscience, specifically developing a franchise of small molecule orexin receptor 2 (OX2R) agonists ¹. The company's strategy is a "pipeline-in-a-pathway" approach, leveraging its understanding of the orexin pathway, structural biology, and translational insights to develop novel OX2R agonists for sleep-wake disorders and other neurological, neurodegenerative, and neuropsychiatric disorders ¹. The core business model revolves around the research and development of these product candidates, with revenue generation currently limited to upfront payments, option exercise fees, and potential milestones and royalties from licensing agreements, rather than product sales ¹.

The company's most advanced product candidate, cleminorexton (formerly ORX750), is an oral, highly potent and selective OX2R agonist in late-stage clinical development for central disorders of hypersomnolence, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) ¹. Cleminorexton is believed to have best-in-class potential across all three indications and first-in-class potential in NT2 and IH ¹. The company is also advancing ORX142 and ORX489, follow-up OX2R agonist candidates, for broader neuroscience indications within neurodegenerative and neuropsychiatric disorders ¹. The earlier stage pipeline includes additional OX2R agonists and research efforts on differentiated pharmacology associated with the orexin pathway ¹.

In addition to its orexin franchise, Centessa Pharmaceuticals plc has a LockBody technology platform, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment while avoiding systemic toxicity ¹. A LockBody is a conditionally-active antibody drug with the potential to engage powerful immune pathways in diseased tissue but not in non-diseased tissue or the periphery ¹. In February 2025, the company entered into a license agreement with Genmab A/S, providing Genmab access to the LockBody technology platform to research products against up to three targets during a multi-year research period, with an option for exclusive commercial licenses ¹.

For the fiscal year ended December 31, 2025, Centessa Pharmaceuticals plc reported cash, cash equivalents, and investments of $577.1 million ². The company has incurred significant net losses since inception and has not generated any revenue from product sales to date ¹. The company expects to continue to incur significant expenses and operating losses for the foreseeable future ¹.

In terms of year-over-year comparisons, the filing does not provide specific revenue growth by segment, margin expansion or contraction, or notable shifts in business mix. However, it highlights the discontinuation of the clinical development of LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody and first-generation LockBody candidate, during the first quarter of 2025 ¹.

Significant operational developments during the reported period include the license agreement with Genmab A/S in February 2025, which provided an upfront payment of $15 million ¹. In November 2025, the company shared preliminary topline data from the completed initial dosing cohorts of cleminorexton within the CRYSTAL-1 study's 2-week crossover design for NT1, NT2, and IH (n=55) as of a September 23, 2025 data cutoff date ¹. Cleminorexton was generally well-tolerated, with statistically significant, clinically meaningful, and dose-dependent improvements in mean sleep latency on the MWT and ESS scores observed in NT1 and NT2 participants, and statistically significant and clinically meaningful improvements in IH participants ¹. Also in November 2025, interim results from the ongoing Phase 1 study of ORX142 in healthy volunteers were announced, showing rapid onset of action, a differentiated PK profile, general tolerability, and statistically significant, dose-dependent improvements in mean sleep latency on the MWT in sleep-deprived participants ¹. During the first quarter of 2026, a Phase 1 FIH study for ORX489 in healthy volunteers was initiated following IND clearance from the FDA ¹. The company also entered into a Loan and Security Agreement with Oxford Finance LLC on December 30, 2024, receiving an initial Term Loan of $110.0 million ³.

Management's specific revenue, margin, or EPS guidance for the upcoming period is not explicitly stated in the filing. However, the company expects cash, cash equivalents, and investments to fund its operations into mid-2028, based on its current operating model and development plans ².

A major growth area for Centessa Pharmaceuticals plc is the continued development of its orexin franchise, particularly cleminorexton, ORX142, and ORX489 ¹. Cleminorexton is in late-stage clinical development for NT1, NT2, and IH, with the ongoing Phase 2a CRYSTAL-1 study aiming to identify optimal doses and regimens for the registrational program ¹. Preliminary data from CRYSTAL-1's 2-week crossover design showed statistically significant and clinically meaningful improvements in key efficacy measures across all three indications ¹. The Phase 1 study of ORX142 in healthy volunteers demonstrated rapid onset of action and dose-dependent improvements in mean sleep latency, informing future patient trials ¹. The Phase 1 FIH study for ORX489 was initiated in the first quarter of 2026 ¹. The company believes its pathway-centric model positions it to establish leadership in orexin-based neuroscience and deliver transformational medicines ¹.

Another growth vector is the LockBody technology platform, which was licensed to Genmab A/S in February 2025 ¹. Under this agreement, Centessa received an upfront payment of $15 million and may receive option exercise fees potentially totaling up to an additional $15 million ⁴. The company is also eligible to receive potential payouts of approximately $230 million in development, regulatory, and sales milestones per product, as well as tiered royalties ranging in the mid-single digits on annual global net licensed product sales ⁴. This collaboration allows Genmab to research products against up to three undisclosed targets during a multi-year research period, with options for exclusive commercial licenses ¹.

Regarding operational outlook, the company anticipates that its expenses will increase substantially as it continues research and preclinical and clinical development of product candidates, initiates additional clinical trials, prepares and submits marketing applications, seeks to discover and develop additional product candidates, establishes sales, marketing, and distribution infrastructure, maintains and expands its intellectual property portfolio, and fulfills future potential payment obligations under incentivization agreements ¹. The company also expects to incur significant losses for the foreseeable future ¹.

Planned capital allocation includes using cash resources to fund the continued development and pre-commercialization costs of clinical-stage product candidates, fund continued development of other pipeline assets (including discovery, manufacturing, research, and development), fund the acquisition of any drug development activities related to new programs, and for working capital and other general corporate purposes ¹. The company will need to seek additional funding in the future, potentially through public or private equity offerings, debt financings, credit or loan facilities, or a combination thereof ¹. The Loan and Security Agreement with Oxford Finance LLC provides access to up to an additional $40.0 million of loan proceeds in an additional tranche, available during a specified period, and an additional $50.0 million may be made available at the Lenders' sole discretion ³.

The company explicitly flags several structural headwinds and execution risks. The proposed transaction with Eli Lilly and Company is subject to customary closing conditions, and failure to complete it within the expected timeframe, or at all, could adversely affect the business and stock price ¹. The company may not be successful in building a pipeline of product candidates with commercial value, and a single or limited number of programs may comprise a large proportion of its value ¹. There is a risk that the company may expend limited resources on a particular product candidate and fail to capitalize on more profitable opportunities ¹. The company faces challenges related to managing expected growth in the scale and complexity of its operations, including retaining employees and finding replacements ¹. The recent CEO transition also presents inherent risks ¹. The company's reliance on a small team of employees located in different geographies and on third parties for manufacturing and clinical trials poses operational challenges and risks of unsatisfactory performance or supply chain disruptions ¹. Geopolitical or macro factors such as the ongoing Russia-Ukraine war, the Middle East conflict(s), tensions in U.S.-China relations, and changes in trade policy, including the imposition of tariffs, could cause disruptions to business activities ¹.

The company faces material risks including the potential failure to complete the proposed acquisition by Eli Lilly and Company, which could result in adverse effects on its business and stock price, including a termination fee of approximately $63 million ¹. Operational risks include the challenge of building a commercially valuable product pipeline, with a large proportion of the company's value residing in a limited number of programs, particularly the orexin program ¹. The company has incurred net losses since inception and expects to continue to do so, requiring substantial additional funds to advance product development ¹. Its loan facility with Oxford Finance contains operating and financial covenants, including a minimum cash covenant commencing October 1, 2026, of (1) 35% of the outstanding principal balance of the Term Loan and (2) up to 80% of the outstanding principal balance of the Term Loan based on clinical data and active development of its lead orexin assets, which could restrict business and financing activities and lead to acceleration of debt obligations if breached ³. Clinical development is a long, expensive, and uncertain process, with product candidates potentially failing at any stage or suffering delays, and success in early trials is not indicative of later results ¹. Regulatory risks include the possibility of not obtaining U.S. or foreign regulatory approval, or approvals being limited, and the FDA may require the company to exceed the current maximum exposure limit for cleminorexton, potentially causing material delays or additional costs ¹. The company relies heavily on third parties for preclinical studies, clinical trials, and manufacturing, exposing it to risks of unsatisfactory performance, supply chain shortages, or defective products ¹. Intellectual property risks involve the potential for insufficient patent protection, challenges to existing patents, and claims of infringement by third parties, which could be costly and time-consuming ¹. Furthermore, the company is subject to stringent and changing privacy laws, regulations, and standards, such as the EU/UK GDPR and CCPA, with potential fines up to 20 million euros (£17.5 million for the UK GDPR) or 4% of global annual revenues for noncompliance ¹. The use of new and evolving technologies, such as artificial intelligence, may present cybersecurity, data privacy, intellectual property, and regulatory risks, with the EU Artificial Intelligence Act imposing significant obligations and potential fines ¹.

Management's message to shareholders emphasizes the company's focus as a clinical-stage biotechnology company pioneering orexin-based neuroscience, with a "pipeline-in-a-pathway" approach to develop a franchise of novel OX2R agonists ¹. They highlight cleminorexton as their most advanced product candidate, in late-stage clinical development for central disorders of hypersomnolence, with best-in-class potential across NT1, NT2, and IH, and first-in-class potential in NT2 and IH ¹. Management also points to the advancement of ORX142 and ORX489 for broader neuroscience indications ¹. A key strategic priority is leveraging their deep understanding of the orexin pathway, differentiated structural biology, and translational insights to deliver transformational medicines and establish leadership in orexin-based neuroscience ¹. Another strategic priority is the opportunistic evaluation and entry into strategic transactions around certain product candidates, targets, geographies, or disease areas, as evidenced by the Genmab license agreement for the LockBody technology platform, which generated an upfront payment of $15 million and potential future milestones and royalties ¹. Management also acknowledges the proposed transaction with Eli Lilly and Company for $38.00 in cash per share, plus contingent value rights up to an aggregate of $9.00 per share, which is expected to close in the third quarter of 2026 ¹.